Table 4. Meta-analysis of miR-499 rs3746444 polymorphism with cancer risk.

Variables	na	C vs. T				CC vs. TT				TC vs. TT				CC+TC vs. TT				CC vs. TC+TT
		OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2
Total	21	1.106(1.005–1.218)	0.040	<0.001	67.2	1.167(0.969–1.405)	0.103	0.042	38.3	1.126(0.985–1.288)	0.081	<0.001	71.9	1.148(1.020–1.292)	0.022	<0.001	69.0	1.100(0.903–1.339)	0.344	0.007	49.4
Cancer type
Breast Cancer	4	1.101(1.006–1.204)	0.036	0.214	33.0	1.165(0.915–1.482)	0.215	0.189	37.1	1.163(0.952–1.420)	0.140	0.047	62.3	1.150(0.973–1.359)	0.102	0.102	51.7	1.065(0.712–1.595)	0.758	0.059	59.8
Colorectal Cancer	2	1.136(0.938–1.375)	0.192	0.161	49.1	1.557(0.670–3.621)	0.304	0.096	63.9	0.867(0.541–1.390)	0.554	0.100	63.0	1.045(0.831–1.314)	0.705	0.964	0.0	1.645(0.611–4.428)	0.325	0.047	74.6
Lung Cancer	2	0.963(0.822–1.129)	0.643	0.828	0.0	0.880(0.538–1.439)	0.610	0.919	0.0	0.981(0.812–1.185)	0.843	0.595	0.0	0.970(0.809–1.163)	0.742	0.682	0.0	0.874(0.537–1.424)	0.589	0.836	0.0
Primary Liver Cancer	4	1.094(0.737–1.623)	0.656	<0.001	83.3	1.187(0.560–2.516)	0.655	0.017	70.5	1.007(0.696–1.458)	0.970	0.048	62.1	1.074(0.685–1.683)	0.757	0.004	77.2	1.201(0.675–2.136)	0.533	0.065	58.6
SCCHN	3	1.290(0.593–2.804)	0.521	<0.001	95.4	1.774(0.429–7.328)	0.429	0.030	78.6	1.220(0.527–2.821)	0.643	<0.001	94.8	1.289(0.751–2.215)	0.357	<0.001	91.9	1.685(0.503–5.643)	0.398	0.061	71.5
other	6	1.103(0.988–1.231)	0.081	0.124	42.2	1.078(0.823–1.413)	0.585	0.494	0.0	1.280(0.935–1.753)	0.123	<0.001	77.7	1.223(0.947–1.579)	0.124	0.006	69.7	0.946(0.730–1.226)	0.675	0.121	42.6
Ethnicity
Caucasian	7	1.003(0.926–1.086)	0.951	0.197	31.8	1.110(0.912–1.352)	0.299	0.233	26.9	0.939(0.846–1.042)	0.236	0.143	39.4	0.997(0.908–1.095)	0.952	0.166	34.3	1.139(0.948–1.368)	0.166	0.088	47.8
Asian	14	1.142(0.999–1.305)	0.052	<0.001	71.5	1.169(0.894–1.529)	0.253	0.036	44.7	1.234(1.035–1.471)	0.019	<0.001	73.9	1.220(1.032–1.442)	0.020	<0.001	73.7	1.039(0.781–1.381)	0.794	0.009	53.4
Design
HB	9	1.188(0.962–1.465)	0.109	<0.001	82.6	1.283(0.910–1.809)	0.156	0.036	53.3	1.163(0.899–1.504)	0.250	<0.001	80.5	1.216(0.965–1.533)	0.097	<0.001	80.7	1.224(1.004–1.491)	0.045	0.101	39.2
PB	10	1.055(0.985–1.130)	0.127	0.088	40.4	1.061(0.881–1.278)	0.533	0.369	7.9	1.142(0.969–1.346)	0.114	0.001	67.4	1.110(0.961–1.282)	0.156	0.006	60.8	0.968(0.808–1.160)	0.726	0.097	41.5
Sample size
≥1000	6	1.031(0.930–1.143)	0.560	0.039	57.4	1.135(0.946–1.362)	0.173	0.259	23.3	0.992(0.913–1.077)	0.840	0.076	49.9	1.015(0.901–1.142)	0.809	0.049	55.1	1.135(0.948–1.359)	0.167	0.293	18.5
<1000	15	1.157(0.996–1.343)	0.056	<0.001	68.7	1.165(0.869–1.562)	0.307	0.030	46.1	1.225(0.985–1.523)	0.068	<0.001	73.7	1.241(1.038–1.485)	0.018	<0.001	68.5	1.043(0.762–1.429)	0.791	0.003	58.5
HWE
Yes	14	1.049(0.939–1.172)	0.397	<0.001	67.8	1.063(0.902–1.252)	0.465	0.275	16.4	1.109(0.952–1.293)	0.184	<0.001	74.0	1.094(0.947–1.265)	0.222	<0.001	73.2	1.006(0.857–1.181)	0.938	0.111	33.0

SCCHN: squamous cell carcinoma of the head and neck; HB: hospital based; PB: population based; HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; P: p value; P-H: P value of Q for heterogeneity test; I²: 0–25%, no heterogeneity; 25–50%, modest heterogeneity; 50%, high heterogeneity;

^aNumber of studies involved.

Random effects model was used when P value of Q for heterogeneity test (P-H)<0.05 or I²>50%; otherwise, fixed effect model was used.